Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Cisplatin, and Docetaxel (PDT) for Induction Therapy in Locally Advanced HNSCC
NCT07214987Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Massachusetts General Hospital. Started Mar 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07214987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214987.